Cargando…

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9

Dyslipidemia is listed among important cardiovascular disease risk factors. Treating lipid disorders is difficult, and achieving desirable levels of LDL-cholesterol (LDL-C) is essential in both the secondary and primary prevention of cardiovascular disease. For many years, statins became the basis o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wołowiec, Łukasz, Osiak, Joanna, Wołowiec, Anna, Wijata, Aleksandra, Grześk, Elżbieta, Kozakiewicz, Mariusz, Banach, Joanna, Nowaczyk, Alicja, Nowaczyk, Jacek, Grześk, Grzegorz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965021/ https://www.ncbi.nlm.nih.gov/pubmed/36839644 http://dx.doi.org/10.3390/pharmaceutics15020323

Ejemplares similares

Soluble Guanylyl Cyclase Activators—Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension
por: Grześk, Grzegorz, et al.
Publicado: (2023)

Beta-blockers in cardiac arrhythmias–Clinical pharmacologist’s point of view
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

The Role of Selected Epigenetic Pathways in Cardiovascular Diseases as a Potential Therapeutic Target
por: Wołowiec, Anna, et al.
Publicado: (2023)

MicroRNA and lncRNA as the Future of Pulmonary Arterial Hypertension Treatment
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

Prognostic Value of Plasma Catestatin Concentration in Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

The Interactions of Nintedanib and Oral Anticoagulants—Molecular Mechanisms and Clinical Implications
por: Grześk, Grzegorz, et al.
Publicado: (2020)

Alcohol and Cardiovascular Diseases—Do the Consumption Pattern and Dose Make the Difference?
por: Chudzińska, Małgorzata, et al.
Publicado: (2022)

Carbon Monoxide and Nitric Oxide as Examples of the Youngest Class of Transmitters
por: Nowaczyk, Alicja, et al.
Publicado: (2021)

Catestatin as a New Prognostic Marker in Stable Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up
por: Wołowiec, Łukasz, et al.
Publicado: (2020)

Current Modulation of Guanylate Cyclase Pathway Activity—Mechanism and Clinical Implications
por: Grześk, Grzegorz, et al.
Publicado: (2021)

Antiepileptic Drug Tiagabine Does Not Directly Target Key Cardiac Ion Channels Kv11.1, Nav1.5 and Cav1.2
por: Kowalska, Magdalena, et al.
Publicado: (2021)

The Clinical Significance of Drug–Food Interactions of Direct Oral Anticoagulants
por: Grześk, Grzegorz, et al.
Publicado: (2021)

Acetylsalicylic Acid–Primus Inter Pares in Pharmacology
por: Fijałkowski, Łukasz, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

Implementation of recommendations on the check of risk factors for cardiovascular diseases in patients undergoing coronary re-interventions
por: Walukiewicz, Marcin, et al.
Publicado: (2023)

PCSK9 signaling pathways and their potential importance in clinical practice
por: Wiciński, Michał, et al.
Publicado: (2017)

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
por: Merćep, Iveta, et al.
Publicado: (2022)

PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
por: Kong, Ni, et al.
Publicado: (2022)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Pentraxin 3 as a Novel Marker in Cardiovascular Diseases?
por: Malinowski, Bartosz, et al.
Publicado: (2011)

The Potential Role of RANTES in Post-Stroke Therapy
por: Pawluk, Hanna, et al.
Publicado: (2023)

Selected Mediators of Inflammation in Patients with Acute Ischemic Stroke
por: Pawluk, Hanna, et al.
Publicado: (2022)

The Role of Selected Pro-Inflammatory Cytokines in Pathogenesis of Ischemic Stroke
por: Pawluk, Hanna, et al.
Publicado: (2020)

Paroxetine—Overview of the Molecular Mechanisms of Action
por: Kowalska, Magdalena, et al.
Publicado: (2021)

Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
por: Rakocevic, Jelena, et al.
Publicado: (2023)

Resveratrol Increases Serum BDNF Concentrations and Reduces Vascular Smooth Muscle Cells Contractility via a NOS-3-Independent Mechanism
por: Wiciński, Michał, et al.
Publicado: (2017)

Artificial Intelligence Technologies in Cardiology
por: Ledziński, Łukasz, et al.
Publicado: (2023)

K(V)11.1, Na(V)1.5, and Ca(V)1.2 Transporter Proteins as Antitarget for Drug Cardiotoxicity
por: Kowalska, Magdalena, et al.
Publicado: (2020)

Effect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis
por: Pawluk, Hanna, et al.
Publicado: (2020)

Increased Oxidative Stress Markers in Acute Ischemic Stroke Patients Treated with Thrombolytics
por: Pawluk, Hanna, et al.
Publicado: (2022)

Synthesis of Biotinylated PAMAM G3 Dendrimers Substituted with R-Glycidol and Celecoxib/Simvastatin as Repurposed Drugs and Evaluation of Their Increased Additive Cytotoxicity for Cancer Cell Lines
por: Wróbel, Konrad, et al.
Publicado: (2022)

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
por: Arnold, Natalie, et al.
Publicado: (2022)

Killer-cell immunoglobulin-like receptor genotype and haplotype combinations in children treated for acute lymphoblastic leukemia
por: Kołtan, Sylwia, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study
por: Grześk, Grzegorz, et al.
Publicado: (2021)

Extended List of Warning Signs in Qualification to Diagnosis and Treatment of Inborn Errors of Immunity in Children and Young Adults
por: Dąbrowska, Anna, et al.
Publicado: (2023)

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment
por: Nowaczyk, Alicja, et al.
Publicado: (2022)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Potential Markers in Cardiac Hypertrophy?
por: Malinowski, Bartosz, et al.
Publicado: (2012)

The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro
por: Uram, Łukasz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kamqtvs85g36dgn5en4g5cu0at